The European Hematology Association Congress 2024 in Madrid discussed CAR-T therapy in the treatment of large B-cell lymphoma. Researchers emphasized the importance of using this therapy in the first-line treatment due to potential changes in disease-related factors. Early and first-line use of CAR-T therapy could benefit patients at high risk of relapse. The management of CAR-T cells is evolving, with strategies like dual CAR-T therapies being explored to overcome resistance mechanisms. Various studies are ongoing to improve the efficacy of CAR-T therapy. Strategies to accelerate cell production times and novel approaches, such as IL-18, are being tested to address current challenges.
Source link
Dual CAR-T Therapies Are Becoming More Established
